Cargando…

No Improvement of Survival for Alveolar Rhabdomyosarcoma Patients After HLA-Matched Versus -Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Compared to Standard-of-Care Therapy

BACKGROUND: Patients with stage IV alveolar rhabdomyosarcoma (RMA) have a 5-year-survival rate not exceeding 30%. Here, we assess the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for these patients in comparison to standard-of-care regimens. We also compare the use of HLA-m...

Descripción completa

Detalles Bibliográficos
Autores principales: Schober, Sebastian Johannes, Hallmen, Erika, Reßle, Florian, Gassmann, Hendrik, Prexler, Carolin, Wawer, Angela, von Luettichau, Irene, Ladenstein, Ruth, Kazanowska, Bernarda, Ljungman, Gustaf, Niggli, Felix, Lohi, Olli, Hauer, Julia, Gruhn, Bernd, Klingebiel, Thomas, Bader, Peter, Burdach, Stefan, Lang, Peter, Sparber-Sauer, Monika, Koscielniak, Ewa, Thiel, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127413/
https://www.ncbi.nlm.nih.gov/pubmed/35619911
http://dx.doi.org/10.3389/fonc.2022.878367